Skip to main content
TLPH
NASDAQ Life Sciences

Talphera 实现关键性 Nephro-Crrt 注册试验 50% 招募里程碑

feedReported by Reuters
Sentiment info
Positive
Importance info
7
Price
$0.869
Mkt Cap
$42.489M
52W Low
$0.38
52W High
$1.57
Market data snapshot near publication time

summarizeSummary

Talphera 宣布其正在进行的 Nephro-Crrt 注册试验已实现 50% 的招募里程碑。这是小型生物科技公司的一项积极的运营更新，表明在关键性临床研究中取得了稳定的进展。达到这一阶段减少了时间表风险，并展示了公司朝着潜在的监管提交和商业化方向的执行力。对于像 Talphera 这样的公司，其估值与管道开发密切相关，这样的里程碑可以积极影响投资者情绪。交易者现在将关注进一步的招募更新、试验完成以及最终的顶级数据。

在该公告发布时，TLPH的交易价格为$0.87，交易所为NASDAQ，所属行业为Life Sciences，市值约为$4248.9万。 52周交易区间为$0.38至$1.57。 这则新闻被评估为积极市场情绪，重要性评分为7/10。 来源：Reuters。

show_chartPrice Chart

Share this article

Copied!

feed TLPH - Latest Insights

TLPH
Apr 29, 2026, 4:31 PM EDT
Filing Type: DEF 14A
Importance Score:
8
Talphera Seeks Shareholder Approval for Significant Equity Plan Expansion Amidst Going Concern Doubts
Sentiment: Negative
View Wiseek Article
TLPH
Apr 01, 2026, 4:37 PM EDT
Filing Type: 424B7
Importance Score:
8
Talphera Finalizes Resale of 7 Million Shares by Selling Stockholders, No Proceeds to Company
Sentiment: Negative
View Wiseek Article
TLPH
Mar 25, 2026, 7:57 PM EDT
Filing Type: 4
Importance Score:
8
CEO Angotti Buys $125K in Shares Amidst Delisting Notice and Going Concern Doubts
Sentiment: Positive
View Wiseek Article
TLPH
Mar 24, 2026, 7:17 PM EDT
Filing Type: S-3
Importance Score:
8
Talphera Registers Over 7 Million Shares for Resale by Selling Stockholders, Including CEO
Sentiment: Negative
View Wiseek Article
TLPH
Mar 23, 2026, 4:05 PM EDT
Filing Type: 10-K
Importance Score:
9
Talphera's 2025 Annual Report Reveals Going Concern, Nasdaq Delisting Risk, and Significant Dilution
Sentiment: Negative
View Wiseek Article
TLPH
Mar 23, 2026, 8:35 AM EDT
Filing Type: 8-K
Importance Score:
7
Talphera Reports Q4/FY25 Results, Boosts Cash to $20.4M, Achieves 50% Enrollment in Key CRRT Study
Sentiment: Neutral
View Wiseek Article
TLPH
Mar 23, 2026, 8:30 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Talphera Reports Q4 Loss, Higher 2026 Expenses Amid 50% Clinical Trial Enrollment
Sentiment: Neutral
View Wiseek Article
TLPH
Mar 16, 2026, 8:30 AM EDT
Filing Type: 8-K
Importance Score:
8
Talphera Closes $4.1M Private Placement Third Tranche at Deep Discount, Issuing Shares and Warrants
Sentiment: Negative
View Wiseek Article
TLPH
Mar 13, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
9
Nasdaq Issues Delisting Warning to Talphera Over Minimum Bid Price
Sentiment: Negative
View Wiseek Article
TLPH
Mar 02, 2026, 8:31 AM EST
Source: Reuters
Importance Score:
7
Talphera Hits 50% Enrollment Milestone in Key Nephro-Crrt Registrational Trial
Sentiment: Positive
View Wiseek Article